The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley signals growing pharmaceutical industry interest in psychedelic drugs for mental health treatment. The move reflects broader acceptance of this previously stigmatized medication class.